[Medical management of arrhythmias; newer antiarrhythmic drugs].
Yamashita
T
T
Second Dept. of Int. Med., Tokyo Univ. Hosp.
Sugimoto
T
T
D000319:Adrenergic beta-Antagonists; D000638:Amiodarone; D000889:Anti-Arrhythmia Agents / Q000145:classification* / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002121:Calcium Channel Blockers; D002722:Chlorobenzenes; D005424:Flecainide; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects; D016293:Moricizine; D010880:Piperidines; D011437:Propylamines; D011725:Pyridines; D015222:Sodium Channels / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002121:Calcium Channel Blockers; D002722:Chlorobenzenes; D010880:Piperidines; D011437:Propylamines; D011725:Pyridines; D015222:Sodium Channels; C063968:E 4031; D016293:Moricizine; C045930:propisomide; C045644:bisaramil; D005424:Flecainide; D000638:Amiodarone; C024318:pirmenol